Urinary CXCL-10, a Prognostic Biomarker for Kidney Graft Injuries: a Systematic Review and Meta-analysis

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Sep 4

PMID 39232662

Authors

Sahar Janfeshan

Afsoon Afshari

Ramin Yaghobi

Jamshid Roozbeh

Affiliations

Soon will be listed here.

Abstract

The challenges of long-term graft survival and the side effects of current immunosuppressive therapies in kidney transplantation highlight the need for improved drugs with fewer adverse effects. Biomarkers play a crucial role in quickly detecting post-transplant complications, with new biomarkers showing promise for ongoing monitoring of disease and potentially reducing the need for unnecessary invasive biopsies. The chemokines such as C-X-C motif chemokine ligand 10 (CXCL10), are particularly promising protein biomarkers for acute renal rejection, with urine samples being a desirable source for biomarkers. The aim of this review is to analyze the literature on the potential role of urinary CXCL10 protein in predicting kidney graft injuries. The results of this study demonstrate that evaluating urinary CXCL10 levels is more successful in identifying post-transplant injuries compared to assessing the CXCL10/Cr ratio.

References

Millan O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B . Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. Br J Clin Pharmacol. 2017; 83(12):2636-2650. PMC: 5698579. DOI: 10.1111/bcp.13399. View

Eikmans M, Gielis E, Ledeganck K, Yang J, Abramowicz D, Claas F . Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies. Front Med (Lausanne). 2019; 5:358. PMC: 6331461. DOI: 10.3389/fmed.2018.00358. View

Van Loon E, Tinel C, de Loor H, Bossuyt X, Callemeyn J, Coemans M . Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study. Am J Kidney Dis. 2023; 83(4):467-476. DOI: 10.1053/j.ajkd.2023.07.022. View

Szumilas K, Wilk A, Wisniewski P, Gimpel A, Dziedziejko V, Kipp M . Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation. Int J Mol Sci. 2023; 24(12). PMC: 10298917. DOI: 10.3390/ijms241210301. View

Wojciechowski D, Wiseman A . Long-Term Immunosuppression Management: Opportunities and Uncertainties. Clin J Am Soc Nephrol. 2021; 16(8):1264-1271. PMC: 8455033. DOI: 10.2215/CJN.15040920. View

Rabant M, Amrouche L, Morin L, Bonifay R, Lebreton X, Aouni L . Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients. Am J Transplant. 2015; 16(6):1868-81. DOI: 10.1111/ajt.13677. View

Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V . Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol. 2015; 26(11):2840-51. PMC: 4625672. DOI: 10.1681/ASN.2014080797. View

Sharaby I, Alksas A, Abou El-Ghar M, Eldeeb M, Ghazal M, Gondim D . Biomarkers for Kidney-Transplant Rejection: A Short Review Study. Biomedicines. 2023; 11(9). PMC: 10525551. DOI: 10.3390/biomedicines11092437. View

Lazzeri E, Rotondi M, Mazzinghi B, Lasagni L, Buonamano A, Rosati A . High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation. 2005; 79(9):1215-20. DOI: 10.1097/01.tp.0000160759.85080.2e. View

10.

Greenblatt D, Ransil B, Harmatz J, Smith T, Duhme D, Koch-Weser J . Variability of 24-hour urinary creatinine excretion by normal subjects. J Clin Pharmacol. 1976; 16(7):321-8. DOI: 10.1002/j.1552-4604.1976.tb01527.x. View

11.

Jackson J, Kim E, Begley B, Cheeseman J, Harden T, Perez S . Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011; 11(10):2228-34. PMC: 3184377. DOI: 10.1111/j.1600-6143.2011.03680.x. View

12.

Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M . Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009; 9(6):1347-53. DOI: 10.1111/j.1600-6143.2009.02645.x. View

13.

Mitch W, Collier V, Walser M . Creatinine metabolism in chronic renal failure. Clin Sci (Lond). 1980; 58(4):327-35. DOI: 10.1042/cs0580327. View

14.

Han H, Lubetzky M . Immune monitoring of allograft status in kidney transplant recipients. Front Nephrol. 2023; 3:1293907. PMC: 10663942. DOI: 10.3389/fneph.2023.1293907. View

15.

Hirt-Minkowski P, Rush D, Gao A, Hopfer H, Wiebe C, Nickerson P . Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. Transplantation. 2016; 100(9):1988-96. DOI: 10.1097/TP.0000000000001304. View

16.

Delanaye P, Rozet E, Krzesinski J, Cavalier E . Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta. 2010; 412(3-4):390. DOI: 10.1016/j.cca.2010.10.011. View

17.

Waikar S, Sabbisetti V, Bonventre J . Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010; 78(5):486-94. PMC: 3025699. DOI: 10.1038/ki.2010.165. View

18.

Hu H, Aizenstein B, Puchalski A, Burmania J, Hamawy M, Knechtle S . Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004; 4(3):432-7. DOI: 10.1111/j.1600-6143.2004.00354.x. View

19.

Tang K, Toh Q, Teo B . Normalisation of urinary biomarkers to creatinine for clinical practice and research--when and why. Singapore Med J. 2015; 56(1):7-10. PMC: 4325562. DOI: 10.11622/smedj.2015003. View

20.

Muhlbacher J, Doberer K, Kozakowski N, Regele H, Camovic S, Haindl S . Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Front Med (Lausanne). 2020; 7:114. PMC: 7160229. DOI: 10.3389/fmed.2020.00114. View